← All trials
NCT06328439
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 19, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Jan 31, 2028
- First posted
- Mar 25, 2024
- Last posted
- Mar 25, 2024
- Enrollment
- 216
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Avistone Biotechnology Co., Ltd.Lead sponsor
- Central South UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOfficial
- Chinese Academy of Medical SciencesCollaborator
- Peking UniversityCollaborator
- Henan Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.